ArticleExtracellular vesicle2026
Advancements in extracellular vesicle research.
Article in Extracellular vesicle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors.
Funding
Abstract
The AAEV (American Association of Extracellular Vesicles) Annual Meeting at the John P. McGovern Commons in Houston, TX convened over 300 leading researchers, clinicians, and industry experts from around the world to advance the rapidly evolving field of extracellular vesicle (EV) science. EVs, nanoscale lipid-bound particles released by all prokaryotic and eukaryotic cells, have emerged as crucial mediators of intercellular communication, trans- porting proteins, nucleic acids, and lipids that influence a wide spectrum of physiological and pathological processes. Their involvement in immune modulation, tissue regeneration, cancer progression, metabolic regulation, and other complex biological functions positions EVs as promising diagnostic biomarkers and therapeutic delivery agents in precision medicine and personalized healthcare. However, significant challenges persist, including the heterogeneity of EV populations, complexities in isolation and purification, and the pressing need for standardized characterization protocols. The 2024 AAEV's annual gathering provided a pivotal forum for exchanging insights and cultivating collaborations. The meeting featured keynote addresses delved into the intricate heterogeneity, biogenesis pathways, and immu- nomodulatory capabilities of EVs, as well as their contributions to disease progression. Subsequent sessions covered a broad range of topics, showcasing cutting-edge technologies for EV isolation and characterization, revealing novel mechanisms by which EVs modulate immune responses and disease states, and presenting innovative EV engineering approaches for delivering therapeutics. Industry presentations complemented academic discussions by introducing scalable EV production systems, automated isolation methods, specialized analytical tools, and strategies to navigate regulatory pathways. Alongside these presentations, the association supports dissemination of the latest discoveries and methodologies through its flagship publication, Extracellular Vesicle (EV). Collectively, the insights shared at the AAEV Annual Meeting underscored the remarkable progress in understanding EV complexity, refining isolation and analysis techniques and translating fundamental discoveries into clinically actionable solutions. Speakers highlighted advanced isolation platforms, refined bioengineering methods, and efforts to integrate EV-based diagnostics and therapeutics into existing clinical frameworks. As the field matures, the forward momentum reflects a transition from theoretical potential to tangible applications. By fostering global collaboration, strengthening ties between academia and industry, and providing platforms like the EV journal, for ongoing dialogue, the EV community is well-positioned to surmount current challenges and accelerate the integration of EV-based approaches into mainstream healthcare.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.